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Conclusion. Treatment time is a factor that could inﬂuence on SBRT uncertainty. In our experience, set-up time is longer the ﬁrst
day of treatment than in the rest of fractions. Dynamic arc therapy is faster than treatment with only ﬁxed ﬁelds. Immobilization
with Bodyﬁx® gives enough accuracy, being our PTV margin of 0.5 cm appropriate according to our data.
http://dx.doi.org/10.1016/j.rpor.2013.03.558
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Purpose. To analyze our experience treating lung tumours with stereotactic body radiation therapy (SBRT), emphasising what
concerns to toxicity.
Materials and methods. We evaluate our results treating patients with stage I lung cancer or lung metastases with SBRT from
August 2011 to December 2012. We describe toxicity using the Common Terminology Criteria for Adverse Events v3.0 (CTCAE).
We evaluate the local control (LC), regional relapse (RR), distant progression (DP) and overall survival (OS).
Results. We have treated eighteen patients in that period with a median age of 74 (54–87). 22% were women and 78% men. The
ECOG performance status was 1 in 72% patients, 2 in 22% and 3 in 5%. Thirteen patients had stage I lung cancer (72%) and ﬁve had
lung metastases (28%). With a median follow up of 6.5 months, 6 patients developed grade 1 pneumonitis (33%) and 2 patients
grade 2 pneumonitis (11%). Two patients had grade 1 chest wall pain. Only one grade 1 dermatitis was observed. The LC was of
100%. Between patients with stage I lung cancer, RR was observed in 6% and DP in 13%. OS was 89%.
Conclusions. With a short median follow-up time our results are coherent with published data, achieving excellent local control
with distant progression as ﬁrst relapse in patients diagnosed of stage I lung cancer. SBRT was well tolerated with no severe
toxicity observed.
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Background. Stereotactic radiosurgery (SRS) delivers a potent, highly focused dose of radiation to the tumor while sparing the
surrounding normal tissues.
Aim. The purpose of this study is to assess the outcome of patients with intracranial meningiomas treated with SRS.
Methods. A total of 73 patients with 221 benign meningiomas treated with SRS and followed up for more than a year were reviewed
between 1991 and 2005. Fifty patients (68%) were treated with SRS to the primary meningioma while 23 (32%) patients received
SRS to the relapses adjacent or distant from the site of the initial meningioma that was previously treated with surgery alone.
Mean tumor margin dose was 14Gy (range, 10–16). SRS was delivered after surgery in 117 meningiomas (55 patients).
Results. The median age at diagnosis was 47 years old (range, 16–74) and the median follow-up 5.8 years (range, 1–13.6). The 3-
and 5-year overall survival rates for all patients were 95% and 90%, respectively. The mean gross tumor volume decreased from
4.17 cm3 to 3.23 cm3 after SRS (P=0.057). Twenty-two (10%) meningiomas increased after SRS. In addition, clinical symptoms
improved in 36% and remained stable in 45%. With regard to morbidity of SRS, only 7 patients (9.6%) had late complications,
including: edema (N=4), brain necrosis (N=4), gliosis (N=1), and paresis of the III pair (N=1). There was no treatment-related
mortality.
Conclusions. SRS for patients with multiple intracranial meningiomas is effective yielding a high local tumor control, whereas the
treatment-related morbidity remains low.
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Introduction. Whole-brain radiation therapy (WBRT) combined with boost on the metastases has demonstrated to improve the
results of the treatment in selected patients in contrast to single WBRT.
